|
5th International AIDS Society Conference on HIV Pathogenesis and TreatmentCape Town - July 19 - 22, 2009 |
HIGH SURVIVAL AND TREATMENT SUCCESS SUSTAINED AFTER UP TO THREE YEARS OF ART FOR CHILDREN IN CAMBODIA
IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: Abstract No. MOAB102
P. Isaakidis1, M.-E. Raguenaud1, V. Te2, C.S. Tray3, K. Akao3, V. Kumar3, S. Ngin4, E. Nerrienet4, R. Zachariah5
1Médecins Sans Frontières , Phnom Penh, Cambodia, 2Donkeo Referral Hospital, Ministry of Health, Pediatrics Department, Takeo, Cambodia, 3Angkor Hospital for Children, Siem Reap, Cambodia, 4Pasteur Institute, HIV/Hepatitis Laboratory, Phnom Penh, Cambodia, 5Médecins Sans Frontières, Brussels, Belgium
BACKGROUND: Long-term outcomes of antiretroviral therapy (ART) in children remain poorly documented in resourcelimited settings.We assessed three year survival, CD4-evolution and virological response among children enrolled in a programmatic setting in Cambodia.
METHODS: Cross-sectional survey within a cohort study. Two pediatric HIV-clinics delivered ART since 2003. Children treated with first-line ART for at least 24 months were assessed with viral load and genotyping. Kaplan-Meier method and Cox regression were used to assess survival and risk factors for treatment failure.
RESULTS: Of 1168 HIV+ children registered, 670 (57%) started ART between January 2003 and December 2007. Survival probability was 0.95 (95%CI:0.93-0.97), 0.93 (95%CI:0.91-0.95) and 0.91 (95%CI:0.88-0.93) at 12, 24 and 36 months respectively. Among 270 eligible children, 268 were assessed for viral load. 128(48%) were female. Median age was 6 years. Median ART duration was 36.2 months (IQR:30.7-40.7). Median CD4 gain for children over 5 years was +304, +704 and +737 cells/ml at 6, 24 and 36 months respectively, while for children under 5 years median CD4% gain was +10.0%, +15.2% and +15.0% at 6, 24 and 36 months. In an intention-to-treat analysis, treatment success ratio was 85%. Among 138 patients who were at least 36 months on ART, 129(93.5%) had undetectable viral load. 22 children had VL>1,000copies/ml and 21/21 presented mutations conferring resistance mostly to lamivudine and NNRTIs. CD4-count below threshold for severe immunosupression at month 24 and 36 predicted failure after month 24 and month 36 respectively .Only 2 out of 22 children with VL>1,000copies/ml met the WHO immunological criteria for failure (Sensitivity=0.1). Orphan status did not predict failure.
CONCLUSIONS: Good survival rate, immunological restoration and viral suppression can be achieved and sustained after three years of ART among children in resource-constrained settings. Increased access to routine virological measurements is needed in these settings to allow for timely and accurate diagnosis of treatment failure.
Download PDF of this abstract.
Download Power Point Presentation.
2009-07-22
MOAB102
Oral Abstract Session MOAB1 - Paediatric ART: Successes and Challenges
Copyright © 2009 - International AIDS Society (IAS). All information and content relating to the abstracts from the 5th International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.